Orion Eyes US Market For Phase III ALS Therapy
Oral Levosimendan May Improve Respiratory Symptoms
Sales grew but operating profits remained flat in 2019 at Orion Group, as the European mid-sized pharma pursued R&D in amyotrophic lateral sclerosis and cancer.
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Amid declining sales of drugs covered by reference prices in Finland, local leader Orion says it has been able to slightly strengthen its market position.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.